Recombinant Rhesus Macaque CD83 Protein Pre-coupled Magnetic Beads

• Cat.No.: CD83-577R-B
• Product Overview: The Recombnant protein was conjugated to magnetic beads. This ready-to-use, pre-coupled magnetic beads are in uniform particle size and narrow size distribution with large surface area, which is conducive to convenient and fast capture target molecules with high specificity and achieve magnetic separation. This product can be equipped with automation equipment for high-throughput operations.

Specification

• Source: HEK293
• Species: Rhesus Macaque
• Form: Solution
• Particle size: ~2 μm
• Beads Surface: Hydrophilic
• Capacity: > 200 pmol rabbit IgG/ mg beads
• Applications: Immunoassay, In vitro diagnostics, cell sorting, Immunoprecipitation/Co-precipitation, Protein/antibody separation and purification.
• Stability: Stable for at least 6 months from the date of receipt of the product under proper storage and handling conditions.
• Storage: 2-8℃. Do not to freeze thaw the Beads
• Concentration: 10mg beads/mL
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: CD83 CD83 molecule [ Macaca mulatta (Rhesus monkey) ]
• Official Symbol: CD83
• Synonyms: CD83; CD83 antigen
• Gene ID: 701825
• mRNA Refseq: NM_001261335
• Protein Refseq: NP_001248264
• UniProt ID: F6WX37

Reviews

03/16/2021

The experimental conditions are wide, and the experimental results are accurate and reproducible.

08/24/2020

The resulting strips are clear and bright, which greatly exceeds the expected results.

06/10/2020

CD83 activity is maintained for a very long time and can be maintained for a long time, which is very stable and reliable.

Q&As

Could CD83 be a target for immunotherapy?

Yes, CD83 can be targeted as immunotherapy. Immunotherapy for CD83 has been explored in several clinical trials with some efficacy.

Are there population differences in CD83 treatment?

It is unclear whether there is a population difference in CD83 treatment. However, due to factors such as individual differences and genetic polymorphisms, different populations may respond differently to treatment. Therefore, population-specific treatment strategies may need to be individually adapted and optimized.

What are possible aspects of future research on CD83?

Future research on CD83 may involve more in-depth molecular mechanism studies, optimization and improvement of CD83-based immunotherapy strategies, and research on combination with other immunotherapies or drugs.

Is there a relationship between CD83 and other immune checkpoint molecules?

CD83 interacts and regulates with other immune checkpoint molecules. Together, they are involved in the regulation of the immune response.

Is CD83 expression regulated by other molecules?

Yes, CD83 expression is regulated by a variety of molecules, including cytokines, transcription factors, and epigenetic modifications.

What is the therapeutic approach for CD83?

Current treatments for CD83 mainly include immunotherapy and gene therapy. Immunotherapy against CD83 works primarily by modulating the function of dendritic cells and T cells.